MedPath

NEURAXPHARM PHARMACEUTICALS S.L.

🇪🇸Spain
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 3:1

Drug Approvals

35

CIMA_AEMPS:28
EMA:7

Drug Approvals

Tuzulby

Authorization Status
Authorised
Approval Date
Feb 28, 2025
EMA

Paxneury

Authorization Status
Authorised
Approval Date
Feb 26, 2025
EMA

Buprenorphine Neuraxpharm

Authorization Status
Authorised
Approval Date
Dec 19, 2024
EMA

Dimethyl fumarate Neuraxpharm

Authorization Status
Authorised
Approval Date
Apr 22, 2024
EMA

Niapelf

Authorization Status
Authorised
Approval Date
Mar 31, 2024
EMA

Briumvi

Authorization Status
Authorised
Approval Date
May 31, 2023
EMA

Buccolam

Authorization Status
Authorised
Approval Date
Sep 4, 2011
EMA

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 3
1 (100.0%)
No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.